Michael Okunewitch
Stock Analyst at Maxim Group
(0.56)
# 3,896
Out of 4,334 analysts
366
Total ratings
38.9%
Success rate
-2.2%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RANI Rani Therapeutics Holdings | Maintained: Buy | $5 | $1.07 | +367.29% | 14 | May 21, 2026 | |
| AIDX 20/20 Biolabs | Maintained: Buy | $5 | - | - | 2 | May 21, 2026 | |
| GILD Gilead Sciences | Upgraded: Buy | $165 | $134.36 | +22.80% | 23 | May 20, 2026 | |
| CTOR Citius Oncology | Rated: Buy | $6 → $4 | $0.8399 | +376.25% | 10 | May 20, 2026 | |
| CMMB Chemomab Therapeutics | Maintained: Buy | $5 | $2.02 | +147.52% | 12 | May 18, 2026 | |
| ACRV Acrivon Therapeutics | Rated: Buy | $7 | $1.75 | +300.00% | 12 | May 18, 2026 | |
| LCTX Lineage Cell Therapeutics | Maintained: Buy | $3 | $1.30 | +130.77% | 15 | May 14, 2026 | |
| DFTX Definium Therapeutics | Maintained: Buy | $40 | $22.50 | +77.78% | 14 | May 11, 2026 | |
| LGVN Longeveron | Downgraded: Hold | n/a | $0.8202 | - | 24 | May 11, 2026 | |
| KPRX Kiora Pharmaceuticals | Maintained: Buy | $12 | $2.56 | +368.75% | 29 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $4.08 | +145.10% | 3 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $1.34 | +497.01% | 22 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.05 | - | 8 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $12 | $2.08 | +476.92% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 | $0.208 | +380.77% | 23 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $11.81 | +1.61% | 10 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $4.63 | +223.97% | 7 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 | $4.32 | +131.48% | 19 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 | $2.89 | -30.80% | 22 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $16.58 | +80.94% | 26 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $3.33 | - | 6 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 | $137.30 | +45.67% | 12 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $3.13 | - | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.7011 | - | 28 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6.9 | $1.13 | +510.62% | 6 | Sep 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $4.14 | n/a | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $0.65 | n/a | 11 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.42 | n/a | 4 | May 9, 2023 |
Rani Therapeutics Holdings
May 21, 2026
Maintained: Buy
Price Target: $5
Current: $1.07
Upside: +367.29%
20/20 Biolabs
May 21, 2026
Maintained: Buy
Price Target: $5
Current: -
Upside: -
Gilead Sciences
May 20, 2026
Upgraded: Buy
Price Target: $165
Current: $134.36
Upside: +22.80%
Citius Oncology
May 20, 2026
Rated: Buy
Price Target: $6 → $4
Current: $0.8399
Upside: +376.25%
Chemomab Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $5
Current: $2.02
Upside: +147.52%
Acrivon Therapeutics
May 18, 2026
Rated: Buy
Price Target: $7
Current: $1.75
Upside: +300.00%
Lineage Cell Therapeutics
May 14, 2026
Maintained: Buy
Price Target: $3
Current: $1.30
Upside: +130.77%
Definium Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $40
Current: $22.50
Upside: +77.78%
Longeveron
May 11, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.8202
Upside: -
Kiora Pharmaceuticals
May 8, 2026
Maintained: Buy
Price Target: $12
Current: $2.56
Upside: +368.75%
May 7, 2026
Maintained: Buy
Price Target: $10
Current: $4.08
Upside: +145.10%
May 6, 2026
Maintained: Buy
Price Target: $8
Current: $1.34
Upside: +497.01%
May 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.05
Upside: -
Apr 9, 2026
Rated: Buy
Price Target: $10 → $12
Current: $2.08
Upside: +476.92%
Apr 8, 2026
Maintained: Buy
Price Target: $1
Current: $0.208
Upside: +380.77%
Mar 26, 2026
Maintained: Buy
Price Target: $12
Current: $11.81
Upside: +1.61%
Mar 25, 2026
Maintained: Buy
Price Target: $15
Current: $4.63
Upside: +223.97%
Mar 17, 2026
Rated: Buy
Price Target: $10
Current: $4.32
Upside: +131.48%
Mar 17, 2026
Maintained: Buy
Price Target: $2
Current: $2.89
Upside: -30.80%
Mar 10, 2026
Reiterated: Buy
Price Target: $30
Current: $16.58
Upside: +80.94%
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $3.33
Upside: -
Mar 5, 2026
Maintained: Buy
Price Target: $200
Current: $137.30
Upside: +45.67%
Dec 3, 2025
Downgraded: Hold
Price Target: n/a
Current: $3.13
Upside: -
Sep 23, 2025
Maintained: Hold
Price Target: n/a
Current: $0.7011
Upside: -
Sep 13, 2025
Maintained: Hold
Price Target: $6.9
Current: $1.13
Upside: +510.62%
Mar 3, 2025
Maintained: Buy
Price Target: $12
Current: $4.14
Upside: n/a
Sep 13, 2024
Maintained: Buy
Price Target: $12
Current: $0.65
Upside: n/a
May 9, 2023
Maintained: Buy
Price Target: n/a
Current: $1.42
Upside: n/a